Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,742
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
S&P 500, Dow Close At Record Levels
The U.S. stock market rallied on Friday, sending the S&P 500 and Dow Jones Industrial Average into record territory, after a surprise stimulus plan from the Bank of Japan was announced.
Top Equities Stories Of The Day
Omega Healthcare to Buy Aviv REIT
Sony Posts Hefty Loss
Starbucks Sales Growth Disappoints; Delivery Is Coming -- 3rdUpdate
Two Picks to Dig Into Pipelines, Shale Energy -- Barron's
U.S. Stocks, Bonds Dip on Fed Outlook
Twitter Demotes Product Chief Daniel Graf
Byron Wien: Slow Growth Good for Stock Market -- Barron's
Jefferies Expected to Book up to $15 Million Loss on Toms Shoes Debt, Sources Say -- Update
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 183413 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist